Boai NKY Medical Holdings Ltd
SZSE:300109

Watchlist Manager
Boai NKY Medical Holdings Ltd Logo
Boai NKY Medical Holdings Ltd
SZSE:300109
Watchlist
Price: 16.81 CNY -2.72% Market Closed
Market Cap: 8.1B CNY
Have any thoughts about
Boai NKY Medical Holdings Ltd?
Write Note

Boai NKY Medical Holdings Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Boai NKY Medical Holdings Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Boai NKY Medical Holdings Ltd
SZSE:300109
Pre-Tax Income
ÂĄ427.8m
CAGR 3-Years
62%
CAGR 5-Years
24%
CAGR 10-Years
30%
Zhejiang Juhua Co Ltd
SSE:600160
Pre-Tax Income
ÂĄ1.8B
CAGR 3-Years
71%
CAGR 5-Years
2%
CAGR 10-Years
24%
Hengli Petrochemical Co Ltd
SSE:600346
Pre-Tax Income
ÂĄ8.2B
CAGR 3-Years
-27%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Satellite Chemical Co Ltd
SZSE:002648
Pre-Tax Income
ÂĄ5.8B
CAGR 3-Years
-1%
CAGR 5-Years
32%
CAGR 10-Years
28%
Jiangsu Eastern Shenghong Co Ltd
SZSE:000301
Pre-Tax Income
-ÂĄ4.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Rongsheng Petrochemical Co Ltd
SZSE:002493
Pre-Tax Income
ÂĄ4.3B
CAGR 3-Years
-47%
CAGR 5-Years
14%
CAGR 10-Years
50%
No Stocks Found

Boai NKY Medical Holdings Ltd
Glance View

Market Cap
8.2B CNY
Industry
Chemicals

Boai NKY Medical Holdings Ltd., founded in the heartland of innovation in Henan Province, China, traces its roots back to an era when the world was rapidly advancing in medical technologies yet still bustling with unmet needs for specialized medical supplies. The company pioneered its focus on producing medical polymer materials and channeled its expertise into the creation of polyvinyl pyrrolidone (PVP), a versatile substance used in pharmaceuticals, cosmetics, and various medical applications. This single compound laid the foundation for the firm's ascent, offering it the placement in the global market where its robust application spans from being a pharmaceutical binder to a blood plasma substitute. The magic of Boai NKY lies in its ability to marry scientific research with commercial execution, ensuring its products meet stringent international standards, thereby opening doors to markets in over 50 countries. The company generates revenue by leveraging its strong manufacturing capabilities and R&D investments. This ensures a steady stream of innovative products catering to the global health industry. Boai NKY's business model diversifies risk by spreading its expertise across biomedicine, cosmetics, agriculture, and food sectors, creating a symbiotic revenue framework. By maintaining a diverse product portfolio and nurturing strategic partnerships, the company builds resilience against market volatility and economic downturns. Its revenue is bolstered not only by domestic sales but by a prominent international presence supported by a network of subsidiaries and distributors. This global footprint ensures a stable cash flow, while continuous investment in technology and quality assurance sustains Boai NKY at the forefront of the competitive chemical manufacturing landscape.

Intrinsic Value
12.92 CNY
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Boai NKY Medical Holdings Ltd's Pre-Tax Income?
Pre-Tax Income
427.8m CNY

Based on the financial report for Sep 30, 2024, Boai NKY Medical Holdings Ltd's Pre-Tax Income amounts to 427.8m CNY.

What is Boai NKY Medical Holdings Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
30%

Over the last year, the Pre-Tax Income growth was -23%. The average annual Pre-Tax Income growth rates for Boai NKY Medical Holdings Ltd have been 62% over the past three years , 24% over the past five years , and 30% over the past ten years .

Back to Top